transforming the detection and treatment of cancer and other complex diseases by harnessing the power of multi-omics data
Impacting millions of lives –
transforming the detection and treatment of cancer and other complex diseases by harnessing the power of multi-omics data
PrognomiQ is developing transformative test products that enable early disease detection and treatment.
We do this by generating proprietary proteomic data at unparalleled volumes and depth of information. We then complement this extensive proteomic information with genomic, metabolomic, and other health data to discover innovative approaches to early disease detection that translate into transformative test products.
PrognomiQ is developing transformative test products that enable early disease detection and treatment.
We do this by generating proprietary proteomic data at unparalleled volumes and depth of information. We then complement this extensive proteomic information with genomic, metabolomic, and other health data to discover innovative approaches to early disease detection that translate into transformative test products.
Untapped proteomic information
Proteomics is the large-scale study of protein molecules to understand their roles in biology. Proteins perform a vast array of functions in the body and cells, including cell development and growth, and disease defense mechanisms. Until now, however, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes. These barriers have now been largely addressed through next-generation tools that enable complex proteomics at scale.
Powerful multi-omics insights
PrognomiQ leverages the latest advances in proteomics to generate direct information of a person’s biological state, including state of disease. This rich proteomic information can be further complemented by additional data sources including genomics and metabolomics. The resulting multi-omics data sets provide unparalleled levels of biological insights, including on the mechanisms of the most complex diseases.
Unlocked disease detection and treatment
We believe that early detection and treatment of complex diseases can only be unlocked through the insights provided by high-quality multi-omics data. Thus, we designed our proprietary multi-omics platform around the most robust methods to generate proteomic, genomic, and metabolomic data at scale. This powerful multi-omics platform is the engine to develop transformative healthcare products that could impact millions of lives.
Our management, board and scientific/clinical scientific advisors include a multidisciplinary group of world-renowned experts in proteomics, multi-omics, data sciences, and clinical medicine.
Leadership Team
Philip Ma, PhD
Chief Executive Officer
Philip Ma is Chief Executive Officer, Founder and Board member for PrognomiQ. Previously, he was Chief Business Officer, President and Founder of Seer. Prior to this, he was Vice-President for Digital Health Technologies and Data Sciences at Biogen, a group that he established to discover insights and create value for Biogen and its patients. Before joining Biogen, Philip was Senior Partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotech sectors, leading the West Coast Healthcare Practice and global Personalized Medicine practice for the Firm. Philip was a macromolecular crystallographer in the lab of Dr. Carl O. Pabo at Massachusetts Institute of Technology, where he received his Ph.D. in Biology. Philip also has degrees in Biochemistry (A.B. from Harvard College) and in Economics (MPhil from Oxford University, where he was a Rhodes Scholar).
Brian Koh
Chief Medical Officer
Brian is the Chief Medical Officer of PrognomiQ. He previously served as Head of Translational Sciences and Clinical Development at Vividion Therapeutics (acquired by Bayer); and earlier in positions of increasing responsibility at both Gilead Sciences and Kite Pharma leading early and late-stage programs for targeted, immuno-oncological, and cellular therapies in both solid and hematological malignancies. Brian received an A.B. in biological anthropology from Harvard College and an M.D., M.S. and M.Phil. from Yale University. At Mayo Clinic – Rochester, he completed a postdoctoral fellowship in clinical pharmacology and postgraduate medical education in internal medicine, hematology, and medical oncology, while holding a triple academic appointment as an instructor in the departments of medicine, oncology, and pharmacology.
David Siewers
CFO
David Siewers is Chief Financial Officer for PrognomiQ. Prior to PrognomiQ, David was Chief Financial Officer for Seer from 2017 to 2020, where he built the accounting and finance function, and supported financing of over $163 million for the company. As CFO of Selecta Biosciences from 2009 to 2017, he also built the finance and accounting organization, and led the company to a successful IPO in June 2016. Before Selecta Biosciences, David built his own successful finance and operations consulting company providing support and guidance to an extensive array of clients ranging from startups to mid-level companies. Prior to creating his own consulting company, David spent over 20 years in the financial services arena as CFO/SVP of Fleet Investment Services (trust and advisory), Fleet Services Corporation (loan, deposit and technology operations) and SVP of Putnam Investments. David graduated from Marietta College and received his CPA in 1978 while working at KPMG.
Bruce Wilcox, PhD
Chief Technology Officer
Bruce Wilcox is the Chief Technology Officer of PrognomiQ. Previously, he was Chief Executive Officer and Founder of DiscernDx. Prior to this, he was Senior Vice President, Research and Development for Applied Proteomics, where he developed and launched the SimpliPro Colon test, a proteomic blood-based test for colon cancer. Earlier in his career, Bruce had multiple R&D leadership roles at Applied Minds, Eksigent Technologies, Nanostream, and Hamilton Sundstrand Sensor Systems, where he supported the development and commercialization of mass spectrometry instruments and systems in multiple applications. Bruce received his Ph.D. in Analytical Chemistry from the University of New Mexico, and his B.S. in Chemistry from North Dakota State University.
Board of Directors
Omid Farokhzad, MD
Chair of the Board of Directors
Dr. Farokhzad is the Chair of PrognomiQ. He is also Chair and Chief Executive Officer of Seer. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 180 papers and is an inventor of over 200 issued and pending patents. Dr. Farokhzad previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB), and Tarveda Therapeutics. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes for his work on nanomaterial surface modification; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.
Tomer Berkovitz, PhD
Board of Directors
Dr. Berkovitz serves on the Board of Directors for PrognomiQ. He is also Partner and CFO at aMoon Fund, a leading global HealthTech & Life Sciences venture capital fund, with over $1 billion under management. Prior to joining aMoon in 2018, he was COO and CFO for Alcobra, a NASDAQ-traded pharmaceutical company that merged with Arcturus Therapeutics. Prior to Alcobra, Mr. Berkovitz was at JP Morgan in their Investment Banking division in New York. He currently serves on the Board of several private healthcare companies. Mr. Berkovitz received his Ph.D. in Finance from Columbia Business School.
Raj Garg, MD, JD
Board of Directors
Dr. Garg serves on the Board of Directors for PrognomiQ. He was formerly CEO, President and Board member of Cancer Treatment Centers of America, a major cancer provider across the U.S., with over 5,000 employees. Previously, he was a Senior Partner at McKinsey & Company, Inc., serving clients in the biopharmaceutical and health care services sectors on strategic and operational topics in the U.S., and globally. Earlier in his career, he practiced law and was a clinician in the state of California. Dr. Garg is also an independent director on the board of Koning Corporation, a next generation breast imaging company. Dr. Garg received his M.D. degree from Stanford University and his J.D. degree from Yale University.
Philip Ma, PhD
Chief Executive Officer
Philip Ma is Chief Executive Officer, Founder and Board member for PrognomiQ. Previously, he was Chief Business Officer, President and Founder of Seer. Prior to this, he was Vice-President for Digital Health Technologies and Data Sciences at Biogen, a group that he established to discover insights and create value for Biogen and its patients. Before joining Biogen, Philip was Senior Partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotech sectors, leading the West Coast Healthcare Practice and global Personalized Medicine practice for the Firm. Philip was a macromolecular crystallographer in the lab of Dr. Carl O. Pabo at Massachusetts Institute of Technology, where he received his Ph.D. in Biology. Philip also has degrees in Biochemistry (A.B. from Harvard College) and in Economics (MPhil from Oxford University, where he was a Rhodes Scholar).
Mark McClellan, MD, PhD
Board of Directors
Dr. McClellan serves on the Board of Directors for PrognomiQ. He is also the Director and Robert J. Margolis MD, Professor of Business, Medicine and Health Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University. Previously, he served as a Senior Fellow in Economic Studies at the Brookings Institution. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services and former commissioner of U.S. Food and Drug Administration (FDA). He previously served as a member of the President’s Council of Economic Advisers, senior director for health care policy at the White House, and Deputy Assistant Secretary for Economic Policy at the Department of the Treasury. Dr. McClellan holds multiple additional roles including, among others: founding chair and former board member, Reagan-Udall Foundation for the FDA; member, National Academy of Medicine; co-chair, guiding committee of the Health Care Payment Learning and Action Network; research associate, National Bureau of Economic Research; and Senior Faculty Advisor, University of Texas Dell Medical School. Dr. McClellan is also an independent director on the boards of Johnson & Johnson, Cigna and Alignment Healthcare.
Isaac Ro
Board of Directors
Mr. Ro serves as an Independent Director on PrognomiQ’s Board. He is also Partner at Catalio Capital Management, a multi-strategy investment fund focused on breakthrough biomedical companies. Prior to joining Catalio in 2023, he was Executive Chairman of Haystack Oncology, a cancer diagnostics company that was acquired by Quest Diagnostics. Before Haystack, Mr. Ro was Chief Financial Officer of Sema4, a NASDAQ traded precision medicine company that merged with GeneDx, a genetic testing company. Previously, he served as Chief Financial Officer of Thrive Earlier Detection, a pioneer in multi-cancer early detection that was acquired by Exact Sciences. Earlier in his career, Mr Ro. was a top ranked equity research analyst at both Goldman Sachs and Leerink Partners where he led a number of IPO’s and equity financings in the Tools and Diagnostics sector. He currently serves on the Board of several private healthcare companies. Mr. Ro received his B.A. with Honors in History from Middlebury College.
Scientific And Clinical Advisors
Catherine Ball, PhD
Scientific Advisor
Dr. Ball serves as Scientific Advisor to PrognomiQ. She was most recently Senior Vice President of Research at Pacific Biosciences, where she led early research and technology development activities. Before joining Pacific Bioscience, she was the Chief Scientific Officer at AncestryDNA, where she led a team of laboratory and data scientists in building the platform and analytics behind the AncestryDNA and AncestryHealth direct-to-consumer products and services. Prior to her time at AncestryDNA, Dr. Ball was a genomic scientist at Stanford University School of Medicine, where she led the Stanford Microarray Database, the largest academic database of its kind. Dr. Ball received a B.S. in Biology and a Ph.D. in Molecular Biology from the University of California, Los Angeles.
Charles Cantor, PhD
Scientific Advisor
Dr. Cantor serves as a Scientific Advisor to PrognomiQ. He is Professor Emeritus of Biomedical Engineering at Boston University. He is also the former Chief Scientific Officer of Sequenom, Inc., a San Diego genetics testing company, and now part of Lab Corp. His research has focused on identifying biological problems that are resistant to conventional analytical approaches and then developing new methodologies or techniques for solving these problems. His laboratory has developed methods for separating large DNA molecules, for studying structural relationships in complex assemblies of proteins and nucleic acids, and for sensitive detection of proteins and nucleic acids in a variety of settings. He is a member of the U.S. National Academy of Science. Dr. Cantor has published more than 400 peer reviewed articles, been granted 54 patents, and co-authored a three-volume textbook on Biophysical Chemistry. He received his A.B. in Chemistry from Columbia University, and his Ph.D. in Biophysical Chemistry from University of California, Berkeley.
Steven Carr, PhD
Scientific Advisor
Dr. Carr serves as a Scientific Advisor to PrognomiQ. He is senior director of proteomics at the Broad Institute of MIT and Harvard, where he is also an institute scientist. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology, chemistry, and medicine. His research has a major focus on the discovery and quantitative verification of biomarkers for major diseases including cancer and cardiovascular and infectious diseases, as well as pharmacodynamics markers of drug response. Prior to returning to academia in 2004, Dr. Carr held scientific leadership positions at GlaxoSmithKline where he was the director of computational and structural sciences and at Millennium Pharmaceuticals where he was senior director of protein science and technology. He has more than 350 publications, and he is deputy editor of Molecular and Cellular Proteomics, the leading journal in the field of proteomics. Dr. Carr received his B.S. from Union College and Ph.D. from MIT.
Vivek F. Farias
Scientific Advisor
Dr. Farias serves as a Scientific Advisor to PrognomiQ. He is the Patrick J. McGovern (1959) Professor at the MIT Sloan School, affiliated with the Operations Management Group and Operations Research Center at MIT. His research focuses on optimization and inference in large-scale stochastic systems. He serves as Department Editor for the Data Science area at Management Science; and serves on the editorial boards of Operations Research and the Informs Journal on Optimization. He was Co-Founder/Chief Technology Officer of Celect, a company focused on advanced analytics solutions for supply chains (acquired by Nike). Dr. Farias received his Ph.D. in Electrical Engineering from Stanford University.
Ernest Fraenkel, PhD
Scientific Advisor
Dr. Fraenkel serves as a Scientific Advisor to PrognomiQ. He is Professor of Biological Engineering at MIT and an Associate Member of the Broad Institute. He is recognized as a leader in the development of novel computational and experimental methods to uncover new therapeutic approaches to disease. His research utilizes multiple experimental methods to measure cellular changes across the genome and proteome, and then computationally integrates these diverse sets of data to reveal novel signaling pathways and regulatory mechanisms that may lead to new therapies for disease. His current projects focus on the study of cancer and neurodegenerative diseases. Dr. Fraenkel received his A.B. from Harvard College and Ph.D. from MIT.
Philip Kantoff, MD
Scientific and Clinical Advisor
Dr. Kantoff serves as Clinical and Scientific Advisor to PrognomiQ. He is also co-founder and CEO of Convergent Therapeutics and Jerome and Nancy Kohlberg Professor Emeritus at Harvard Medical School. He was previously the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK), where he oversaw a department of almost 500 physicians. Before joining MSK, he was the Jerome and Nancy Kohlberg Chair at Harvard Medical School and served as the Director of the Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, Vice Chair of the Department of Medical Oncology, and Chair of the Executive Committee on Clinical Research at the Dana-Farber Cancer Institute. Dr. Kantoff’s research focused on developing improved treatments for patients with genitourinary cancers, including understanding the molecular basis of prostate cancer. He served as Chairman of Prostate Cancer Foundation’s Global Research Council. Dr. Kantoff received his undergraduate and medical degrees from Brown University.
Robert Langer, Sc.D.
Scientific Advisor
Dr. Langer serves as Scientific Advisor to PrognomiQ. He is one of 11 Institute Professors at the Massachusetts Institute of Technology. Dr. Langer’s scientific work, particularly in drug delivery systems and tissue engineering, has been cited over 328,000 times with an H-Index of 282 and his inventions include over 1400 issued or pending patents. He is the youngest person ever elected to all three U.S. National Academies (Science, Engineering, and Medicine). He is one of 3 living individuals to have won both the U.S. National Medal of Science (2006) and the U.S. National Medal of Technology and Innovation (2011); and he has won over 220 other major awards. He served as a member of the U.S. FDA’s Science Board from 1995-2002 and as its Chairman from 1999-2002. Dr. Langer has co-founded over 40 companies, including Moderna, Momenta, Seer, Frequency Therapeutics, Puretech, and Sigilon. Dr. Langer has a bachelor’s degree in chemical engineering from Cornell University and an Sc.D. in chemical engineering from MIT.
Mark Lee, MD, PhD
Scientific and Clinical Advisor
Dr. Lee serves as a Scientific and Clinical Advisor to PrognomiQ. He is the co-founder of N-Power Medicine, a company that aims to accelerate innovation in cancer therapeutics by transforming the clinical trials process for community oncologists. He was most recently Senior Vice President and Global Head for Personalized Healthcare, Product Development at Genentech/Roche. Prior to joining Genentech, Mark was a member of the founding leadership team and Head of Clinical Development and Medical Affairs at GRAIL, where his team built one of the largest clinical research programs in genomic medicine aimed at early cancer detection. His previous roles include Lead for Oncology Clinical Sciences at Google[x] Life Sciences, Chief Medical Officer at Boreal Genomics, and Vice President of Oncology Development at Genomic Health, where he led the successful development and validation of the Oncotype DX Colon and Prostate Cancer Assays. Mark received a PhD in Biological Chemistry and Molecular Pharmacology from Harvard, and a MD from Stanford University, where he completed his internal medicine residency and medical oncology fellowship.
Klaus Lindpaintner, M.D., M.P.H
Scientific and Clinical Advisor
Dr. Lindpaintner serves as a Scientific and Clinical Advisor to PrognomiQ. He was most recently Chief Medical and Scientific Officer at InterVenn Biosciences. Previously, he was Vice President and Global Head, Human Genetics & Computational Medicine at Pfizer. He has also served as Chief Scientific Officer at Thermo Fisher Scientific, and as Chief Scientific Officer at SDIX. Earlier in his career, he was Vice President, Roche Center for Medical Genomics & Roche Distinguished Scientist at Roche Pharmaceuticals, and Associate Professor, Harvard University. Dr. Lindpaintner received his M.D. from Leopold-Franzens Universität Innsbruck, and a Masters of Public Health (M.P.H.) from Harvard. He is board certified in internal medicine, cardiology, and clinical and molecular genetics.
Alfred Sandrock, Jr., MD, PhD
Scientific and Clinical Advisor
Dr. Sandrock serves as a Scientific and Clinical Advisor to PrognomiQ. He is also Chief Executive Officer and Board member for Voyager Therapeutics. Previously, he was Executive Vice President, Research & Development at Biogen and served on the Executive Committee. He has also served as Head of Research & Development, Chief Medical Officer, and other senior executive positions at Biogen, including Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandrock received his B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) at Massachusetts General Hospital.
Cristian Tomasetti, PhD
Scientific Advisor
Dr. Tomasetti serves as a Scientific Advisor to PrognomiQ. He is Director of the Center for Cancer Prevention and Early Detection at City of Hope. He is also Professor and Director of the Division of Mathematics for Cancer Evolution and Early Detection in the Department of Computational and Qualitative Medicine at the Beckman Research Institute, City of Hope and Professor and Director of the Division of Integrated Cancer Genomics, at the Translational Genomics Research Institute. Dr. Tomasetti is recognized for his seminal contributions to our current understanding of cancer etiology and tumor evolution. His research combines mathematical modeling, statistical analysis, and machine learning, with experimental, epidemiological and DNA sequencing data. His current efforts include developing new technologies and classification algorithms for the early detection of cancer via simple blood tests. Dr. Tomasetti received his Ph.D. in Applied Mathematics from the University of Maryland, College Park, followed by a Postdoc in the Department of Biostatistics of the Harvard School of Public Health and the Dana-Farber Cancer Institute.
Wendy Winckler, PhD
Scientific Advisor
Dr. Winckler serves as Scientific Advisor to PrognomiQ. She is also Chief Scientific Officer for Droplet Biosciences. Before joining Droplet Biosciences, she was the Chief Scientific Officer at Glympse Bio, where she led the development of a novel protease activity diagnostic platform with programs in NASH and other disease areas. Prior to her time at Glympse Bio, Dr. Winckler was Executive Director at Novartis Institute for BioMedical Research, where she led Next Generation Diagnostics. Before joining Novartis, she was Director of the Genetic Analysis Platform at the Broad Institute. Dr. Winckler received a B.S. in Microbiology and Molecular Genetics from U from the University of California, Los Angeles, and a Ph.D. in Genetics from Harvard University.
Philip Ma, PhD
:
Philip Ma is Chief Executive Officer, Founder and Board member for PrognomiQ. Previously, he was Chief Business Officer, President and Founder of Seer. Prior to this, he was Vice-President for Digital Health Technologies and Data Sciences at Biogen, a group that he established to discover insights and create value for Biogen and its patients. Before joining Biogen, Philip was Senior Partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotech sectors, leading the West Coast Healthcare Practice and global Personalized Medicine practice for the Firm. Philip was a macromolecular crystallographer in the lab of Dr. Carl O. Pabo at Massachusetts Institute of Technology, where he received his Ph.D. in Biology. Philip also has degrees in Biochemistry (A.B. from Harvard College) and in Economics (MPhil from Oxford University, where he was a Rhodes Scholar).
Brian Koh
:
Brian is the Chief Medical Officer of PrognomiQ. He previously served as Head of Translational Sciences and Clinical Development at Vividion Therapeutics (acquired by Bayer); and earlier in positions of increasing responsibility at both Gilead Sciences and Kite Pharma leading early and late-stage programs for targeted, immuno-oncological, and cellular therapies in both solid and hematological malignancies. Brian received an A.B. in biological anthropology from Harvard College and an M.D., M.S. and M.Phil. from Yale University. At Mayo Clinic – Rochester, he completed a postdoctoral fellowship in clinical pharmacology and postgraduate medical education in internal medicine, hematology, and medical oncology, while holding a triple academic appointment as an instructor in the departments of medicine, oncology, and pharmacology.
David Siewers
:
David Siewers is Chief Financial Officer for PrognomiQ. Prior to PrognomiQ, David was Chief Financial Officer for Seer from 2017 to 2020, where he built the accounting and finance function, and supported financing of over $163 million for the company. As CFO of Selecta Biosciences from 2009 to 2017, he also built the finance and accounting organization, and led the company to a successful IPO in June 2016. Before Selecta Biosciences, David built his own successful finance and operations consulting company providing support and guidance to an extensive array of clients ranging from startups to mid-level companies. Prior to creating his own consulting company, David spent over 20 years in the financial services arena as CFO/SVP of Fleet Investment Services (trust and advisory), Fleet Services Corporation (loan, deposit and technology operations) and SVP of Putnam Investments. David graduated from Marietta College and received his CPA in 1978 while working at KPMG.
Bruce Wilcox, PhD
:
Bruce Wilcox is the Chief Technology Officer of PrognomiQ. Previously, he was Chief Executive Officer and Founder of DiscernDx. Prior to this, he was Senior Vice President, Research and Development for Applied Proteomics, where he developed and launched the SimpliPro Colon test, a proteomic blood-based test for colon cancer. Earlier in his career, Bruce had multiple R&D leadership roles at Applied Minds, Eksigent Technologies, Nanostream, and Hamilton Sundstrand Sensor Systems, where he supported the development and commercialization of mass spectrometry instruments and systems in multiple applications. Bruce received his Ph.D. in Analytical Chemistry from the University of New Mexico, and his B.S. in Chemistry from North Dakota State University.
Omid Farokhzad, MD
:
Dr. Farokhzad is the Chair of PrognomiQ. He is also Chair and Chief Executive Officer of Seer. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 180 papers and is an inventor of over 200 issued and pending patents. Dr. Farokhzad previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB), and Tarveda Therapeutics. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes for his work on nanomaterial surface modification; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.
Tomer Berkovitz, PhD
:
Dr. Berkovitz serves on the Board of Directors for PrognomiQ. He is also Partner and CFO at aMoon Fund, a leading global HealthTech & Life Sciences venture capital fund, with over $1 billion under management. Prior to joining aMoon in 2018, he was COO and CFO for Alcobra, a NASDAQ-traded pharmaceutical company that merged with Arcturus Therapeutics. Prior to Alcobra, Mr. Berkovitz was at JP Morgan in their Investment Banking division in New York. He currently serves on the Board of several private healthcare companies. Mr. Berkovitz received his Ph.D. in Finance from Columbia Business School.
Raj Garg, MD, JD
:
Dr. Garg serves on the Board of Directors for PrognomiQ. He was formerly CEO, President and Board member of Cancer Treatment Centers of America, a major cancer provider across the U.S., with over 5,000 employees. Previously, he was a Senior Partner at McKinsey & Company, Inc., serving clients in the biopharmaceutical and health care services sectors on strategic and operational topics in the U.S., and globally. Earlier in his career, he practiced law and was a clinician in the state of California. Dr. Garg is also an independent director on the board of Koning Corporation, a next generation breast imaging company. Dr. Garg received his M.D. degree from Stanford University and his J.D. degree from Yale University.
Philip Ma, PhD
:
Philip Ma is Chief Executive Officer, Founder and Board member for PrognomiQ. Previously, he was Chief Business Officer, President and Founder of Seer. Prior to this, he was Vice-President for Digital Health Technologies and Data Sciences at Biogen, a group that he established to discover insights and create value for Biogen and its patients. Before joining Biogen, Philip was Senior Partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotech sectors, leading the West Coast Healthcare Practice and global Personalized Medicine practice for the Firm. Philip was a macromolecular crystallographer in the lab of Dr. Carl O. Pabo at Massachusetts Institute of Technology, where he received his Ph.D. in Biology. Philip also has degrees in Biochemistry (A.B. from Harvard College) and in Economics (MPhil from Oxford University, where he was a Rhodes Scholar).
Mark McClellan, MD, PhD
:
Dr. McClellan serves on the Board of Directors for PrognomiQ. He is also the Director and Robert J. Margolis MD, Professor of Business, Medicine and Health Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University. Previously, he served as a Senior Fellow in Economic Studies at the Brookings Institution. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services and former commissioner of U.S. Food and Drug Administration (FDA). He previously served as a member of the President’s Council of Economic Advisers, senior director for health care policy at the White House, and Deputy Assistant Secretary for Economic Policy at the Department of the Treasury. Dr. McClellan holds multiple additional roles including, among others: founding chair and former board member, Reagan-Udall Foundation for the FDA; member, National Academy of Medicine; co-chair, guiding committee of the Health Care Payment Learning and Action Network; research associate, National Bureau of Economic Research; and Senior Faculty Advisor, University of Texas Dell Medical School. Dr. McClellan is also an independent director on the boards of Johnson & Johnson, Cigna and Alignment Healthcare.
Isaac Ro
:
Mr. Ro serves as an Independent Director on PrognomiQ’s Board. He is also Partner at Catalio Capital Management, a multi-strategy investment fund focused on breakthrough biomedical companies. Prior to joining Catalio in 2023, he was Executive Chairman of Haystack Oncology, a cancer diagnostics company that was acquired by Quest Diagnostics. Before Haystack, Mr. Ro was Chief Financial Officer of Sema4, a NASDAQ traded precision medicine company that merged with GeneDx, a genetic testing company. Previously, he served as Chief Financial Officer of Thrive Earlier Detection, a pioneer in multi-cancer early detection that was acquired by Exact Sciences. Earlier in his career, Mr Ro. was a top ranked equity research analyst at both Goldman Sachs and Leerink Partners where he led a number of IPO’s and equity financings in the Tools and Diagnostics sector. He currently serves on the Board of several private healthcare companies. Mr. Ro received his B.A. with Honors in History from Middlebury College.
Catherine Ball, PhD
:
Dr. Ball serves as Scientific Advisor to PrognomiQ. She was most recently Senior Vice President of Research at Pacific Biosciences, where she led early research and technology development activities. Before joining Pacific Bioscience, she was the Chief Scientific Officer at AncestryDNA, where she led a team of laboratory and data scientists in building the platform and analytics behind the AncestryDNA and AncestryHealth direct-to-consumer products and services. Prior to her time at AncestryDNA, Dr. Ball was a genomic scientist at Stanford University School of Medicine, where she led the Stanford Microarray Database, the largest academic database of its kind. Dr. Ball received a B.S. in Biology and a Ph.D. in Molecular Biology from the University of California, Los Angeles.
Charles Cantor, PhD
:
Dr. Cantor serves as a Scientific Advisor to PrognomiQ. He is Professor Emeritus of Biomedical Engineering at Boston University. He is also the former Chief Scientific Officer of Sequenom, Inc., a San Diego genetics testing company, and now part of Lab Corp. His research has focused on identifying biological problems that are resistant to conventional analytical approaches and then developing new methodologies or techniques for solving these problems. His laboratory has developed methods for separating large DNA molecules, for studying structural relationships in complex assemblies of proteins and nucleic acids, and for sensitive detection of proteins and nucleic acids in a variety of settings. He is a member of the U.S. National Academy of Science. Dr. Cantor has published more than 400 peer reviewed articles, been granted 54 patents, and co-authored a three-volume textbook on Biophysical Chemistry. He received his A.B. in Chemistry from Columbia University, and his Ph.D. in Biophysical Chemistry from University of California, Berkeley.
Steven Carr, PhD
:
Dr. Carr serves as a Scientific Advisor to PrognomiQ. He is senior director of proteomics at the Broad Institute of MIT and Harvard, where he is also an institute scientist. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology, chemistry, and medicine. His research has a major focus on the discovery and quantitative verification of biomarkers for major diseases including cancer and cardiovascular and infectious diseases, as well as pharmacodynamics markers of drug response. Prior to returning to academia in 2004, Dr. Carr held scientific leadership positions at GlaxoSmithKline where he was the director of computational and structural sciences and at Millennium Pharmaceuticals where he was senior director of protein science and technology. He has more than 350 publications, and he is deputy editor of Molecular and Cellular Proteomics, the leading journal in the field of proteomics. Dr. Carr received his B.S. from Union College and Ph.D. from MIT.
Vivek F. Farias
:
Dr. Farias serves as a Scientific Advisor to PrognomiQ. He is the Patrick J. McGovern (1959) Professor at the MIT Sloan School, affiliated with the Operations Management Group and Operations Research Center at MIT. His research focuses on optimization and inference in large-scale stochastic systems. He serves as Department Editor for the Data Science area at Management Science; and serves on the editorial boards of Operations Research and the Informs Journal on Optimization. He was Co-Founder/Chief Technology Officer of Celect, a company focused on advanced analytics solutions for supply chains (acquired by Nike). Dr. Farias received his Ph.D. in Electrical Engineering from Stanford University.
Ernest Fraenkel, PhD
:
Dr. Fraenkel serves as a Scientific Advisor to PrognomiQ. He is Professor of Biological Engineering at MIT and an Associate Member of the Broad Institute. He is recognized as a leader in the development of novel computational and experimental methods to uncover new therapeutic approaches to disease. His research utilizes multiple experimental methods to measure cellular changes across the genome and proteome, and then computationally integrates these diverse sets of data to reveal novel signaling pathways and regulatory mechanisms that may lead to new therapies for disease. His current projects focus on the study of cancer and neurodegenerative diseases. Dr. Fraenkel received his A.B. from Harvard College and Ph.D. from MIT.
Philip Kantoff, MD
:
Dr. Kantoff serves as Clinical and Scientific Advisor to PrognomiQ. He is also co-founder and CEO of Convergent Therapeutics and Jerome and Nancy Kohlberg Professor Emeritus at Harvard Medical School. He was previously the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK), where he oversaw a department of almost 500 physicians. Before joining MSK, he was the Jerome and Nancy Kohlberg Chair at Harvard Medical School and served as the Director of the Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, Vice Chair of the Department of Medical Oncology, and Chair of the Executive Committee on Clinical Research at the Dana-Farber Cancer Institute. Dr. Kantoff’s research focused on developing improved treatments for patients with genitourinary cancers, including understanding the molecular basis of prostate cancer. He served as Chairman of Prostate Cancer Foundation’s Global Research Council. Dr. Kantoff received his undergraduate and medical degrees from Brown University.
Robert Langer, Sc.D.
:
Dr. Langer serves as Scientific Advisor to PrognomiQ. He is one of 11 Institute Professors at the Massachusetts Institute of Technology. Dr. Langer’s scientific work, particularly in drug delivery systems and tissue engineering, has been cited over 328,000 times with an H-Index of 282 and his inventions include over 1400 issued or pending patents. He is the youngest person ever elected to all three U.S. National Academies (Science, Engineering, and Medicine). He is one of 3 living individuals to have won both the U.S. National Medal of Science (2006) and the U.S. National Medal of Technology and Innovation (2011); and he has won over 220 other major awards. He served as a member of the U.S. FDA’s Science Board from 1995-2002 and as its Chairman from 1999-2002. Dr. Langer has co-founded over 40 companies, including Moderna, Momenta, Seer, Frequency Therapeutics, Puretech, and Sigilon. Dr. Langer has a bachelor’s degree in chemical engineering from Cornell University and an Sc.D. in chemical engineering from MIT.
Mark Lee, MD, PhD
:
Dr. Lee serves as a Scientific and Clinical Advisor to PrognomiQ. He is the co-founder of N-Power Medicine, a company that aims to accelerate innovation in cancer therapeutics by transforming the clinical trials process for community oncologists. He was most recently Senior Vice President and Global Head for Personalized Healthcare, Product Development at Genentech/Roche. Prior to joining Genentech, Mark was a member of the founding leadership team and Head of Clinical Development and Medical Affairs at GRAIL, where his team built one of the largest clinical research programs in genomic medicine aimed at early cancer detection. His previous roles include Lead for Oncology Clinical Sciences at Google[x] Life Sciences, Chief Medical Officer at Boreal Genomics, and Vice President of Oncology Development at Genomic Health, where he led the successful development and validation of the Oncotype DX Colon and Prostate Cancer Assays. Mark received a PhD in Biological Chemistry and Molecular Pharmacology from Harvard, and a MD from Stanford University, where he completed his internal medicine residency and medical oncology fellowship.
Klaus Lindpaintner, M.D., M.P.H
:
Dr. Lindpaintner serves as a Scientific and Clinical Advisor to PrognomiQ. He was most recently Chief Medical and Scientific Officer at InterVenn Biosciences. Previously, he was Vice President and Global Head, Human Genetics & Computational Medicine at Pfizer. He has also served as Chief Scientific Officer at Thermo Fisher Scientific, and as Chief Scientific Officer at SDIX. Earlier in his career, he was Vice President, Roche Center for Medical Genomics & Roche Distinguished Scientist at Roche Pharmaceuticals, and Associate Professor, Harvard University. Dr. Lindpaintner received his M.D. from Leopold-Franzens Universität Innsbruck, and a Masters of Public Health (M.P.H.) from Harvard. He is board certified in internal medicine, cardiology, and clinical and molecular genetics.
Alfred Sandrock, Jr., MD, PhD
:
Dr. Sandrock serves as a Scientific and Clinical Advisor to PrognomiQ. He is also Chief Executive Officer and Board member for Voyager Therapeutics. Previously, he was Executive Vice President, Research & Development at Biogen and served on the Executive Committee. He has also served as Head of Research & Development, Chief Medical Officer, and other senior executive positions at Biogen, including Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandrock received his B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) at Massachusetts General Hospital.
Cristian Tomasetti, PhD
:
Dr. Tomasetti serves as a Scientific Advisor to PrognomiQ. He is Director of the Center for Cancer Prevention and Early Detection at City of Hope. He is also Professor and Director of the Division of Mathematics for Cancer Evolution and Early Detection in the Department of Computational and Qualitative Medicine at the Beckman Research Institute, City of Hope and Professor and Director of the Division of Integrated Cancer Genomics, at the Translational Genomics Research Institute. Dr. Tomasetti is recognized for his seminal contributions to our current understanding of cancer etiology and tumor evolution. His research combines mathematical modeling, statistical analysis, and machine learning, with experimental, epidemiological and DNA sequencing data. His current efforts include developing new technologies and classification algorithms for the early detection of cancer via simple blood tests. Dr. Tomasetti received his Ph.D. in Applied Mathematics from the University of Maryland, College Park, followed by a Postdoc in the Department of Biostatistics of the Harvard School of Public Health and the Dana-Farber Cancer Institute.
Wendy Winckler, PhD
:
Dr. Winckler serves as Scientific Advisor to PrognomiQ. She is also Chief Scientific Officer for Droplet Biosciences. Before joining Droplet Biosciences, she was the Chief Scientific Officer at Glympse Bio, where she led the development of a novel protease activity diagnostic platform with programs in NASH and other disease areas. Prior to her time at Glympse Bio, Dr. Winckler was Executive Director at Novartis Institute for BioMedical Research, where she led Next Generation Diagnostics. Before joining Novartis, she was Director of the Genetic Analysis Platform at the Broad Institute. Dr. Winckler received a B.S. in Microbiology and Molecular Genetics from U from the University of California, Los Angeles, and a Ph.D. in Genetics from Harvard University.
Be a part of the team transforming healthcare
Careers at PrognomiQ
We are passionate about transforming healthcare by enabling the early detection and treatment of cancer and other complex diseases. Our team values passion, collaboration and the desire to tackle the toughest scientific and clinical challenges with confidence and humility. We strive to have a meaningful impact on the world.
Join us as we open new doorways into disease detection and treatment.
We are passionate about transforming healthcare by enabling the early detection and treatment of cancer and other complex diseases. Our team values passion, collaboration and the desire to tackle the toughest scientific and clinical challenges with confidence and humility. We strive to have a meaningful impact on the world.
Join us as we open new doorways into disease detection and treatment.
